WHO ICTRP trial
Surufatinib combined with toripalimab, albumin - bound paclitaxel and…
ChiCTR2600116673 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2600116673 |
|---|---|
| Public title | Surufatinib combined with toripalimab, albumin - bound paclitaxel and radiotherapy for first - line treatment of advanced esophageal cancer:A single - arm, open - label, phase II clinical study |
| Scientific title | Surufatinib combined with toripalimab, albumin-bound paclitaxel and radiotherapy for first - line treatment of advanced esophageal cancer:A single - arm, open - label, phase II clinical study |
| Primary sponsor | Department of Radiation Oncology, the First Medical Center, Chinese People's Liberation Army (PLA) General Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Esophageal cancer |
| Interventions | Experimental Group:Surufatinib combined with albumin - bound paclitaxel and toripalimab |
| Registration date | Jan 13, 2026 |
| Target size | Experimental Group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: